Mark Friesen joined SK Life Science, Inc. in 2011 and is currently the Global Head of Project Management. With previous work in drug safety and project management, Mark brings a broad level of expertise to SK Life Science, Inc. to help lead its project and portfolio management teams.

Mark has worked for 25 years prior in various project management capacities at mid and large pharmaceutical companies as well as one IT company. Through his experiences and knowledge, he’s been successful in helping to drive SK Life Science, Inc. to their first NDA submission in 2018.

Prior to joining the company, Mark worked with the following pharmaceutical companies: Wyeth-Ayerst Research, Novartis, Knoll Pharmaceuticals, Eisai, Abbott, and Merck. At these companies, Mark gained a vast amount of experience in early, late stage and life cycle management, drug metabolism and some toxicology as well as overall project management and leadership.

Mark earned his bachelor’s degree in chemistry, food and nutrition from Rutgers College and a master’s in technology management from Steven’s Institute of Technology. In addition, Mark has two project management certifications.